Retatrutide 20mg (LY3437943)

Name: Retatrutide 20mg
Brand: Volta Peptides
SKU: vp-001
Price: 99.00 USD
Availability: InStock

Research Use Only

23 sold this week9 people viewing this

$99 USD

Ordering above $1,000?Wholesale pricing →

All orders dispatched within 24hrs

Application formLyophilized powder

StorageRefrigerated

Purity98%

Weight20mg

CAS Number2381089-83-2

Research Use Only

For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.

Retatrutide is a novel triple-hormone receptor agonist peptide designed for advanced metabolic research. This 20mg vial provides ample material for extended in vitro study protocols. Manufactured under strict quality control with HPLC verification.

Related Research News

Regulatory

Retatrutide Monthly Research Cost in Australia Breakdown

Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.

May 12, 2026

Clinical Trials

Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss

Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.

Jun 19, 2026

Clinical Trials

Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26

Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.

Jun 19, 2026